Skip to Content
Merck

Management of epidermolysis bullosa acquisita.

Dermatologic clinics (2011-09-20)
Lizbeth R A Intong, Dédée F Murrell
ABSTRACT

Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone. Treatment is quite challenging because this disease can be recalcitrant to multiple modalities. This article discusses the current management of this disease.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sulfapyridine melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfapyridine, VETRANAL®, analytical standard
Supelco
Sulfapyridine, ≥99.0%